Spatial tissue analysis developer Akoya nets $50M in funding

Cells
Over the past year, Akoya introduced two research platforms focused on spatial biomarker analysis and evaluating the immune system within the tumor microenvironment. (Pixabay)

Akoya Biosciences, developers of spatial tissue and biomarker analysis hardware, has raised $50 million to help boost its commercialization and lay more in-roads into research, drug development and clinical testing markets.

The financing was led by Piper Jaffray’s merchant banking division, with returning investments from Telegraph Hill Partners. Other backers included Agilent Technologies and Innovatus Capital Partners.

Over the past year, Akoya introduced two research platforms. Its Codex fluidics system integrates with fluorescent microscopes to provide spatial, multiplexed biomarker analysis, using a barcode system composed of antibodies and oligonucleotides.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

Meanwhile its Phenoptics immunofluorescence portfolio—acquired in late 2018 from PerkinElmer, along with the team’s management, sales and support staff—is geared toward profiling cancer cells and their interactions with the immune system within the tumor microenvironment. The system includes the Mantra, Vectra and Vectra Polaris workstations and instruments.

“Akoya is transforming how immunotherapies are developed, from discovery of novel biomarkers in the tumor microenvironment to deploying high throughput, highly sensitive information to direct patient therapies,” said Thomas Schnettler, managing director at Piper Jaffray, who joined the company’s board of directors. “Our investment represents our confidence in Akoya’s relentless execution to deliver the next generation of pathology tools.”

In early November, the company launched two new kits for the Vectra Polaris system focused on profiling PD-1 and PD-L1 in lung cancer and melanoma. Each includes six immunofluorescence markers designed to evaluate the checkpoints and their suppression of immune system responses.

Akoya is also working with Precision for Medicine, formerly known as ApoCell, to develop solid tumor and liquid biopsies aimed at guiding the development of new immuno-oncology drug candidates.

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19.